Schedule V is the lowest-abuse-potential tier of federally controlled substances, and it’s the only schedule where federal law permits certain products to be sold without a prescription at all — commonly referred to as “exempt narcotics,” typically low-dose codeine-containing cough preparations. That “no prescription needed” status leads a lot of pharmacists to assume these sales are essentially unregulated. They’re not. They come with their own recordkeeping, quantity, and purchaser-verification requirements that are easy to overlook precisely because there’s no prescription triggering the usual dispensing workflow.
What qualifies as an OTC Schedule V product
Federal law allows certain Schedule V products to be distributed without a prescription only when they meet specific criteria — generally: the product contains limited quantities of a specified narcotic (most commonly codeine) in combination with non-narcotic active ingredients, and the sale is made by a pharmacist personally (not a technician or clerk) under whatever additional conditions federal and state law impose. This exemption is narrow and product-specific — not every Schedule V drug qualifies, and reformulated or differently-dosed versions of an otherwise-exempt product may not meet the exemption criteria. Confirm exempt status for a specific product against current DEA guidance rather than assuming based on the drug name alone.
Federal recordkeeping requirements for exempt sales
Even without a prescription, federal regulations require the dispensing pharmacist to maintain specific records for these sales, generally including:
- Purchaser’s name and address
- Date of sale
- Name and quantity of product sold
- Purchaser identification, typically requiring the pharmacist to be reasonably satisfied of the purchaser’s identity (a form of ID verification)
- The dispensing pharmacist’s initials or identification on the record
Federal rules also generally limit the quantity that can be sold to the same purchaser within a defined time period without a prescription, and require a waiting period consideration between purchases — the specific quantity and time thresholds are set in federal regulation and should be confirmed against current DEA rules rather than relied on from memory, since these figures matter for actual compliance and are outside the scope of a general overview like this one.
Where state requirements go further than federal law
Federal law sets a floor, and a number of states impose stricter requirements on top of it. This is a pattern that shows up throughout controlled substance regulation — state rules layering on top of DEA baseline requirements rather than simply mirroring them. Variations pharmacists commonly encounter include:
- Some states require a prescription for products that qualify as exempt under federal law, effectively eliminating the OTC pathway within that state regardless of federal permission
- Some states impose stricter quantity or frequency limits than the federal minimums
- Some states require PDMP reporting or checking for exempt narcotic sales, even though these sales don’t involve a prescription — treating the sale similarly to a dispensed controlled substance for monitoring purposes
- Some states require additional purchaser age verification or ID documentation beyond what federal law specifies
Because of this layering, “federally exempt” does not automatically mean “sellable without a prescription in my state.” Pharmacists working across state lines — or corporate pharmacy chains setting policy across multiple states — need to confirm the state-level rule independently of the federal exemption status. This is conceptually similar to how gabapentin scheduling varies by state even though gabapentin isn’t federally scheduled at all — state boards regularly impose stricter controls than the federal floor for products they consider to carry meaningful abuse or diversion risk.
The logbook itself
Most pharmacies maintain a dedicated exempt narcotic logbook (paper or electronic) separate from prescription records, specifically because these sales don’t generate a normal prescription record in the pharmacy system. This logbook is a required part of demonstrating compliance and is something DEA and state board inspectors will typically ask to review during a routine inspection. Gaps or inconsistencies in this log — missing purchaser information, unclear pharmacist attribution, or entries that suggest quantity limits weren’t tracked — are a common finding in inspections precisely because the OTC nature of the sale makes staff less rigorous about it than they are with prescription-based controlled substance dispensing.
Where this fits into broader diversion control
Exempt narcotic sales are a recognized diversion vector precisely because they bypass the prescription-based controls that apply to the rest of Schedule II-V dispensing. Pharmacies should treat the recordkeeping and purchaser-verification requirements here with the same seriousness as prescription-based controlled substance handling — this connects to the broader diversion monitoring obligations covered in our piece on DEA diversion reporting requirements, since patterns of unusual exempt narcotic purchasing (frequent purchases, multiple purchasers at the same address, purchases just under quantity thresholds) are the kind of activity pharmacies are expected to notice and act on.
Bottom line
Schedule V OTC sales are a narrow federal exemption with real recordkeeping obligations attached, and state law frequently narrows or eliminates that exemption further. Product eligibility, quantity/time limits, and state-specific overlays all matter for compliance and change periodically — confirm current requirements against DEA regulations and your specific state board or pharmacy law before relying on this overview for an actual dispensing decision.
RxByState tracks controlled substance scheduling and state-specific pharmacy requirements — including where states diverge from federal Schedule V rules — across all 50 states. Start a free 14-day trial →